Country: England
What infection type does your test focus on? Upper and Lower Respiratory Tract
What does your test detect? 20 blood biomarkers and SARS-CoV-2 antigens
About the Team:
Attomarker is focused on nanophotonic biochemical testing. Founded in 2008, Attomarker spun out from Professor Andrew Shaw’s research group at the University of Exeter.
Attomarker works in the personalised medicine market and is committed to providing gold-standard rapid diagnostics to enable better and more timely decisions about health and health interventions.
Attomarker have developed a hand-held device that can measure 20 blood biomarkers from a 5 microlitre blood sample in 7 minutes. The device docks on the user’s iPhone and interrogates a single-use chip. The iPhone camera reads the intensity changes on a nanophotonic array from which the target biomarker species tests results are determined. The device communicates with the cloud to deliver information (anonymously) for public health monitoring.
The technology provides a small-form-factor device that can be used by clinician’s before making an antibiotic prescription. For instance, a C reactive protein (CRP) test can be used for the differential diagnosis of respiratory tract infections.
Twitter: @attomarker
